Home/Pipeline/BBIBP-CorV

BBIBP-CorV

COVID-19

ApprovedCommercial

Key Facts

Indication

COVID-19

Phase

Approved

Status

Commercial

Company

Sinopharm

About Sinopharm

Sinopharm is a Fortune Global 500 company and China's largest pharmaceutical conglomerate, encompassing drug distribution, manufacturing, research and development, and healthcare services. The company gained global recognition for developing one of China's first approved COVID-19 vaccines (BBIBP-CorV) and has established itself as a key player in international vaccine diplomacy. With operations spanning across multiple therapeutic areas and a vast distribution network, Sinopharm serves as a critical component of China's healthcare infrastructure.

View full company profile

Therapeutic Areas

Vaccines Infectious Diseases Traditional Chinese Medicine Generic Drugs Biologics

Other COVID-19 Drugs

Drug	Company	Phase	Status
COVID-19 Severity Prediction Test	Age Labs	Development	Active
Remdesivir (Veklury)	Gilead Sciences	Approved	Commercial
mRNA-1273 (Spikevax)	Moderna	Approved	Commercial
Investigational Oral COVID-19 Antiviral	Shionogi	Clinical	Active
ZyCoV-D	Zydus Lifesciences	Approved	Commercial
SARS-CoV-2 Neutralizing Antibodies	Adaptive Biotechnologies	Discovery	Candidates identified
Covovax™	Novavax	Approved/Commercial	WHO EUL-approved
LY-CoV555 (Bamlanivimab)	AbCellera	Emergency Use Authorization (Past)	Program Completed
ARCT-154 (Bivalent)	Arcturus Therapeutics	Phase 1/2	Active
LUNAR-COV19 (ARCT-021)	Arcturus Therapeutics	Phase 1/2	Completed
Paxlovid (Nirmatrelvir) Manufacturing Enzyme	Codexis	Commercial	Completed Supply